A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer
Neuroendocrine Carcinomas
Solid Tumor Show to Express DLL3

Interventions

DRUG: IDE849
DRUG: durvalumab
DRUG: IDE161

Sponsor

IDEAYA Biosciences